Loading...
•
Sep 30, 2021
Corbus Pharmaceuticals Q3 2021 Earnings Report
Reported third quarter results and provided corporate updates.
Key Takeaways
Corbus Pharmaceuticals reported a net loss of $2.2 million for Q3 2021, with revenue from awards and licenses at $97,000. Operating expenses decreased by $21.2 million compared to the same period last year. The company's cash and investments on hand of $108 million are expected to fund operations into the first quarter of 2024.
Advanced integrin program from preclinical development toward the clinic.
Expanded pipeline through strategic transactions remains a key priority.
Cash and investments on hand of $108 million sufficient to support execution of research, clinical and operational goals into the first quarter of 2024.
Topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus is on track and expected in Q4 2021.
Forward Guidance
Corbus Pharmaceuticals expects its cash and investments to fund operations into the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...